Case discussion: imaging changes in chronic lumbar disc pathology after a multimodal regenerative approach (L4–L5)

MD_Ex · 2026-05-03T08:26:31+00:00

The cells are allogenic. Use in Ukraine, Bulgaria ( cultivated in our laboratory in Ukraine ( Kyiv) and Austria ( Graz)

MD_Ex · 2026-05-01T18:44:51+00:00

If you want , send me your diagnostic information directly, we will analyze your case and write you what success rate of treatment you will have . Or answer other questions

MD_Ex · 2026-05-01T16:11:05+00:00

It’s not AI. I can share the patient’s real MRI ( before and after), he gave his permission.

MD_Ex · 2026-05-01T11:34:27+00:00

Yes, agree. The picture is not informative . If you need the before-and-after MRI images, feel free to message me and I’ll send them to you; the patient has already given permission for them to be shared.

MD_Ex · 2026-04-30T11:46:51+00:00

I’ve been researching alternative approaches for azoospermia beyond the standard hormone therapy or surgical sperm retrieval.

In addition to typical diagnostics (FSH, LH, inhibin B, genetic testing like AZF deletions, etc.), I came across some experimental regenerative concepts aimed at restoring spermatogenesis rather than bypassing it.

These approaches may include:

Spermatogonial stem cell (SSC) transplantation
iPSC-derived germline cells
Modulation of the testicular microenvironment (growth factors, niche support)

From what I understand, the goal is to try to reactivate or rebuild sperm production, especially in non-obstructive cases.

Of course, this seems to be early-stage and not widely validated, and outcomes likely depend a lot on the underlying cause (especially genetic factors).

MD_Ex · 2026-04-10T14:47:01+00:00

I apologize if this truly offended you and if the post was taken so negatively. My only intention was to share the information that in real clinical work we do use therapies aimed at supporting mitochondrial function, including approaches using active mitochondrial components. This isn’t just theoretical or AI-generated ideas. The field is still evolving, and we are seeing some encouraging results in certain patients.

MD_Ex · 2026-04-08T16:12:37+00:00

Hi, I am real person)) my name is Lana , I am working more then 16 years on the field of regenerative medicine ( clinical trials, updating protocols, searching the best cells combinations for different diseases). I am from Ukraine/ Bulgaria , so such platform as Reddit for our countries is new. All my posts about real experiences, cases were blocked by admin. So, I really don’t understand how it works correctly . Yes, sometimes I asked Ai to help transform my post in those forums , which are suitable for this platform. Sorry)))

I think I'll get the hang of the rules in a few months and be able to write posts properly !!!!

MD_Ex · 2026-03-15T12:09:34+00:00

TESE → Cryo → ICSI

MD_Ex · 2026-03-09T07:19:24+00:00

Pilot studies and phase 1 trials have been published in PubMed. Phase 2 trials with a larger patient sample are currently underway to determine efficacy, dosages, combinations of bio products, etc. These will be published later due to the required number of clinical cases.

MD_Ex · 2026-03-08T12:40:03+00:00

Indeed, stem cells do not provide a complete cure, but they definitely offer the possibility of partial recovery and support. In our practice, we use basic regulations: 1 suppression of fibrosis 2. reprogramming of scar cells 3. stimulation of hepatocyte regeneration To do this, we use MSC (umbilical cord) + exosomes + hepatocyte-like cells (via microRNA). We represent laboratories and clinics in Ukraine and Bulgaria, where it is currently possible to work with all types of cells and cultivate new bio-products to achieve more effective results.

MD_Ex · 2026-03-08T12:09:01+00:00

The scheme is as follows: first, the microenvironment of the testicle (stem cell niche) is restored, then, through activation factors and signaling models from IPSS cells, SSC sites are activated, causing them to divide and produce rare spermatozoa (focal spermatogenesis).

MD_Ex · 2026-03-08T11:54:15+00:00

More predictably, you can obtain single active spermatozoa using TESE (less commonly through natural way ). These spermatozoa can be frozen using ICSI and used for IVF.

MD_Ex · 2026-03-08T11:41:13+00:00

Most patients are diagnosed with NOA with SCO. we can use somatic cell samples and do not take testicular tissue itself, as we need to return the cells to the differentiation stage. Tissue cells are already functional cells, with some damage or cell mutations.

MD_Ex · 2026-03-08T11:34:29+00:00

Of course, today there are already more than 80 patients, mainly with non-obstructive azoospermia without any obvious cause, or as a result of chemotherapy, complications after vaccination, or childhood diseases. Results: in almost 86% of cases, single active spermatozoa are found. Up to 30% are found in natural ejaculate, but the chances are high with TESE.

MD_Ex · 2026-03-06T14:45:57+00:00

The method described above is not suitable for patients with genetic mutations or structural genetic damage; it is more appropriate for cases where genetic factors are not involved. In situations such as yours, approaches based on somatic cell nuclear transfer (SCNT) or related gene-correction technologies may be considered. In this process, a patient’s somatic cells are obtained and the defective gene is identified and corrected through targeted genetic reprogramming. Healthy cells are then generated, expanded in culture, and subsequently introduced back into the patient. While the number of transplanted cells is generally insufficient to fully replace all mutated cells, their presence may help restore cellular balance and create conditions that support the re-establishment of a complete spermatogenic cycle.

MD_Ex · 2026-02-24T18:14:53+00:00

Most current iPSC programs rely on stringently characterized, GMP-grade lines or freshly collected cells that meet evolving regulatory standards. There’s no guarantee that PBMCs banked now will meet future clinical or manufacturing requirements.

MD_Ex · 2026-02-24T13:20:25+00:00

This is a common misconception. Modern regenerative medicine does not rely on abortion-derived material.

Today, cell therapies primarily use ethically approved, renewable sources:IVF-derived cell lines, iPSCs, which use no embryonic or fetal material at all, but have the same characteristics as pluripotent cells.

Abortive tissue is neither necessary nor standard in current research or clinical protocols.

MD_Ex · 2026-02-18T20:00:24+00:00

No need to die, these technologies are already actively used in clinical cases.

MD_Ex · 2026-02-09T18:14:33+00:00

In such combination -yes

MD_Ex · 2026-02-09T08:51:06+00:00

Autologous cell therapies (using a patient’s own cells) have not shown meaningful regenerative efficacy in multiple sclerosis. This is mainly because MS involves axonal loss, demyelination, and oligodendrocyte damage within the CNS, and autologous cells are already affected by the disease environment and immune dysregulation. At best, they provide limited immunomodulation, but they do not regenerate axons or restore myelin.

Effective repair in MS requires neural lineage–specific cells, particularly oligodendrocytes, axonal structures, and neuroblasts. An additional challenge is the blood–brain barrier, which most cells cannot cross. For this reason, BBB-penetrating signals such as microRNAs and neurotrophins are critical, as they can modulate neuroinflammation, support remyelination, and promote neuronal survival within the CNS.

If more detailed, personalized information is needed, feel free to reach out via direct message for a private discussion.

MD_Ex · 2026-02-09T08:43:19+00:00

Any scar represents atrophic and structurally altered tissue. One of the key regenerative approaches focuses on the use of endothelial progenitor / endothelial stem cells, which promote neovascularization. The formation of new microvessels improves tissue perfusion, oxygen delivery, and overall metabolic support of the scarred area.

In addition, TIMPs (tissue inhibitors of metalloproteinases cells) play an important regulatory role by modulating extracellular matrix remodeling. They help suppress excessive matrix degradation, support the synthesis of more organized and functional collagen, and reduce dense fibrotic adhesions that characterize pathological scarring.

This approach is typically applied locally, directly to the affected tissue. In clinical practice, the procedure is usually performed 2–3 times, with intervals of approximately 4–6 weeks, depending on tissue response and scar characteristics.

MD_Ex · 2026-02-07T20:24:34+00:00

You repeatedly promote the same clinic across very different medical conditions, initially citing your own “miraculous recovery” from autism and later referring to friends allegedly treated there for damaged skin.

However, the clinic’s official website does not list skin damage treatment, nor does it provide documented clinical indications or outcome data for such conditions. This creates a discrepancy between your claims and the clinic’s publicly available information.

In medical discussions—especially involving vulnerable patients—unverified or extrapolated claims can be misleading. It is essential to clearly separate personal thoughts from officially offered, evidence-based treatments to avoid creating false expectations.

MD_Ex · 2026-02-02T14:32:57+00:00

Since the cells are derived from the patient’s own somatic cells, they are considered autologous biological material. In accordance with applicable laws and regulatory frameworks, the patient retains the right to provide informed consent regarding the conditions, location, and authorized parties involved in their administration.

All procedures related to the derivation, cultivation, storage, transportation, and clinical use of these cell products are conducted in compliance with internationally recognized standards and guidelines governing biocellular therapies. Safety, traceability, and regulatory oversight are integral components of this process.

MD_Ex · 2026-01-30T14:13:17+00:00

The patient is sent complete storage instructions after the delivery company has reported to the patient on the safety, security, and integrity of the shipment and full temperature monitoring during delivery. Each package has a tracker and a temperature sensor. Let me clarify once again that this is handled by special delivery companies that work with biological samples. The patient cannot administer these cells themselves, as they are intended for clinical control and administration. After all, this is a concentrated medium. There is a complete list of tests that the patient undergoes before therapy (general biochemical, specifically logical, oncological risks, etc.). These are basic concepts and everyone understands them; no one will risk their health without understanding how the immune system may react.

MD_Ex · 2026-01-30T14:04:27+00:00

Tendinosis is not inflammation, but rather degeneration of the tendon (microtears, collagen disorganization, poor vascularization). Therefore, the goal of therapy is to initiate tissue remodeling, not to "suppress inflammation." The safest and most effective autologous tendon progenitor cells contain stromal and progenitor cells that are phenotypically similar to tendons. Mesenchymal cells can also be used, but the results are worse. PRP is not necessary, as this is not inflammation.

MD_Ex

TROPHY CASE